Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Tenax Therapeutics (Nasdaq: TENX) announced that President & CEO Chris Giordano will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenax Therapeutics (Nasdaq: TENX) announced that President & CEO Chris Giordano will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. A live and archived webcast will be available via the company’s investor relations webpage.
Details
News Market Reaction – TENX
On Sep 1, the day this news came out, TENX closed 2.17% below the previous close. Argus tracked a peak move of +6.2% during that session. Our momentum scanner recorded 14 alerts in the available session data.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Presentation Date
- September 9, 2026
- 2026 Cantor Global Healthcare Conference
- Presentation Time
- 8:35 a.m. ET
- September 9, 2026 presentation
Historical Context
-
Primary and key secondary endpoints were not met in the LEVEL trial
-
Quarterly net loss and research spending increased year over year
-
Options covering 160,000 shares were granted to three newly hired employees
-
Phase 3 LEVEL data received a late-breaking ESC Congress presentation slot
-
Cash runway and Phase 3 program updates accompanied quarterly financial results
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET.
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.